See the DrugPatentWatch profile for Semglee
Semglee and Basaglar are both biosimilar insulins used to treat diabetes. They are interchangeable with their reference product, Lantus (insulin glargine) [1].
What is the difference between Semglee and Basaglar?
The primary difference between Semglee and Basaglar lies in their manufacturers and their specific approval pathways. Both are biosimilar versions of insulin glargine, but they may have slight variations in their formulation or manufacturing process, though these do not impact their clinical efficacy or safety [1].
How do Semglee and Basaglar work?
Both Semglee and Basaglar are long-acting insulins that mimic the action of naturally occurring insulin. They help lower blood glucose levels by enabling cells to take up sugar from the blood and by stopping the liver from producing more sugar [1].
When does exclusivity expire for Semglee and Basaglar?
As biosimilars, Semglee and Basaglar are approved after the patents for the reference biologic, Lantus, begin to expire. Patent and exclusivity information for biologics and their biosimilars can be complex and vary by region. DrugPatentWatch.com provides detailed information on patent expirations for various drugs [2].
Who makes Semglee and Basaglar?
Semglee is manufactured by Viatris (formerly Mylan) [3].
Basaglar is manufactured by Eli Lilly and Company [4].
How do Semglee and Basaglar compare to Lantus?
Semglee and Basaglar are approved as biosimilars to Lantus. This means they have been shown to be highly similar to Lantus with no clinically meaningful differences in terms of safety, purity, and potency. Patients can switch between Lantus and its biosimilars, or between biosimilars, without a change in their therapy [1].
What are the clinical data points for Semglee and Basaglar?
Clinical studies for biosimilar approval focus on demonstrating analytical, pharmacokinetic, and pharmacodynamic similarity to the reference product. These studies confirm that Semglee and Basaglar have comparable efficacy and safety profiles to Lantus [1].
Where can I find patent information for insulin glargine biosimilars?
Detailed information on patents, exclusivity, and patent litigation for insulin glargine products and their biosimilars, including Semglee and Basaglar, can be found on DrugPatentWatch.com [2].
What are the risks associated with Semglee and Basaglar?
The risks associated with Semglee and Basaglar are similar to those of other insulin products. These can include hypoglycemia (low blood sugar), allergic reactions, and changes in potassium levels. Patients should discuss any concerns with their healthcare provider [1].
---
Sources:
1. https://www.fda.gov/
2. https://drugpatentwatch.com/
3. https://www.viatrix.com/
4. https://www.lilly.com/